spikevax bivalent original/omicron (elasomeran and imelasomeran) covid-19 vaccine 0.1 mg/ml suspension for injection vial
moderna australia pty ltd - elasomeran, quantity: 0.05 mg/ml; imelasomeran, quantity: 0.05 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; water for injections; trometamol; sodium acetate trihydrate; sucrose; distearoylphosphatidylcholine; cholesterol; glacial acetic acid; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; trometamol hydrochloride - spikevax bivalent original/omicron (elasomeran/imelasomeran) covid-19 vaccine has provisional approval for the indication below:,as a booster dose for active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 18 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of immunogenicity and short-term safety data. continued approval depends on the evidence of longer term benefits and safety from ongoing clinical trials and post-market assessment.
spikevax bivalent original/omicron (elasomeran and imelasomeran) covid-19 vaccine 0.1 mg/ml suspension for injection pre-filled syringe
moderna australia pty ltd - elasomeran, quantity: 0.05 mg/ml; imelasomeran, quantity: 0.05 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; water for injections; trometamol; sodium acetate trihydrate; sucrose; distearoylphosphatidylcholine; cholesterol; glacial acetic acid; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; trometamol hydrochloride - spikevax bivalent original/omicron (elasomeran/imelasomeran) covid-19 vaccine has provisional approval for the indication below: as a booster dose for active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of immunogenicity and short-term safety data. continued approval depends on the evidence of longer term benefits and safety from ongoing clinical trials and post-market assessment.
spikevax bivalent original/omicron ba.4-5 (elasomeran/davesomeran) covid-19 vaccine 0.1 mg/ml suspension for injection vial
moderna australia pty ltd - elasomeran, quantity: 0.05 mg/ml; davesomeran, quantity: 0.05 mg/ml - injection, suspension - excipient ingredients: 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; distearoylphosphatidylcholine; heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; sucrose; trometamol; cholesterol; trometamol hydrochloride; sodium acetate trihydrate; water for injections; glacial acetic acid - spikevax bivalent original/omicron ba.4-5 (elasomeran/davesomeran) covid-19 vaccine is indicated for:,as a booster dose for active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19.,the use of this vaccine should be in accordance with official recommendations.
spikevax bivalent original/omicron ba.4-5 (elasomeran/davesomeran) covid-19 vaccine 0.1 mg/ml suspension for injection pre-filled syringe
moderna australia pty ltd - davesomeran, quantity: 0.05 mg/ml; elasomeran, quantity: 0.05 mg/ml - injection, suspension - excipient ingredients: water for injections; cholesterol; glacial acetic acid; heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; trometamol; sucrose; distearoylphosphatidylcholine; sodium acetate trihydrate; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; trometamol hydrochloride - spikevax bivalent original/omicron ba.4-5 (elasomeran/davesomeran) covid-19 vaccine is indicated for:,as a booster dose for active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19.,the use of this vaccine should be in accordance with official recommendations.
spikevax bivalent original/omicron ba.4-5 (elasomeran/davesomeran) covid-19 vaccine 0.1 mg/ml suspension for injection vial-single dose
moderna australia pty ltd - elasomeran, quantity: 0.05 mg/ml; davesomeran, quantity: 0.05 mg/ml - injection, suspension - excipient ingredients: 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; distearoylphosphatidylcholine; heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; sucrose; trometamol; cholesterol; trometamol hydrochloride; sodium acetate trihydrate; water for injections; glacial acetic acid - spikevax bivalent original/omicron ba.4-5 (elasomeran/davesomeran) covid-19 vaccine is indicated for:,as a booster dose for active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19.,the use of this vaccine should be in accordance with official recommendations.
spikevax (elasomeran) covid-19 vaccine 0.2 mg/ml suspension for injection vial
moderna australia pty ltd - elasomeran, quantity: 0.2 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; trometamol hydrochloride; trometamol; water for injections; cholesterol; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; sodium acetate trihydrate; sucrose; distearoylphosphatidylcholine; glacial acetic acid - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment. active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.
spikevax (elasomeran) covid-19 vaccine 0.1 mg/ml suspension for injection pre-filled syringe
moderna australia pty ltd - elasomeran, quantity: 0.1 mg/ml - injection, suspension - excipient ingredients: cholesterol; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride; glacial acetic acid; sodium acetate trihydrate; sucrose; water for injections; heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and postmarket assessment spikevax (elasomeran) covid-19 vaccine is indicated for: active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.
spikevax (elasomeran) covid-19 vaccine 0.1 mg/ml suspension for injection vial
moderna australia pty ltd - elasomeran, quantity: 0.1 mg/ml - injection, suspension - excipient ingredients: heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate; cholesterol; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride; glacial acetic acid; sodium acetate trihydrate; sucrose; water for injections; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 - spikevax (elasomeran) covid-19 vaccine has provisional approval for the indication below:active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 months of age to <6 years of age. the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of short-term efficacy and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment. spikevax (elasomeran) covid-19 vaccine is indicated for: active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2 in individuals 6 years of age and older. the use of this vaccine should be in accordance with official recommendations.
wormaway 20mg spot-on solution for small cats and kittens
chanelle pharmaceuticals manufacturing limited - praziquantel - spot-on solution - 20 mg/pipette - praziquantel
prazpronto 40 mg spot-on solution for medium cats
chanelle pharmaceuticals manufacturing limited - praziquantel - spot-on solution - 40 milligram(s) - praziquantel